Pregabalin Mitigates Microglial Activation and Neuronal Injury by Inhibiting HMGB1 Signaling Pathway in Radiation-Induced Brain Injury
Zhang Zhan,Jiang Jingru,He Yong,Cai Jinhua,Xie Jiatian,Wu Minyi,Xing Mengdan,Zhang Zhenzhen,Chang Haocai,Yu Pei,Chen Siqi,Yang Yuhua,Shi Zhongshan,Liu Qiang,Sun Haohui,He Baixuan,Zeng Junbo,Huang Jialin,Chen Jiongxue,Li Honghong,Li Yi,Lin Wei-Jye,Tang Yamei
DOI: https://doi.org/10.1186/s12974-022-02596-7
IF: 9.3
2022-01-01
Journal of Neuroinflammation
Abstract:Abstract Background Radiation-induced brain injury (RIBI) is the most serious complication of radiotherapy in patients with head and neck tumors, which seriously affects the quality of life. Currently, there is no effective treatment for patients with RIBI, and identifying new treatment that targets the pathological mechanisms of RIBI is urgently needed. Methods Immunofluorescence staining, western blotting, quantitative real-time polymerase chain reaction (Q-PCR), co-culture of primary neurons and microglia, terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay, enzyme-linked immunosorbent assay (ELISA), and CRISPR–Cas9-mediated gene editing techniques were employed to investigate the protective effects and underlying mechanisms of pregabalin that ameliorate microglial activation and neuronal injury in the RIBI mouse model. Results Our findings showed that pregabalin effectively repressed microglial activation, thereby reducing neuronal damage in the RIBI mouse model. Pregabalin mitigated inflammatory responses by directly inhibiting cytoplasmic translocation of high-mobility group box 1 (HMGB1), a pivotal protein released by irradiated neurons which induced subsequent activation of microglia and inflammatory cytokine expression. Knocking out neuronal HMGB1 or microglial TLR2/TLR4/RAGE by CRISPR/Cas9 technique significantly inhibited radiation-induced NF-κB activation and pro-inflammatory transition of microglia. Conclusions Our findings indicate the protective mechanism of pregabalin in mitigating microglial activation and neuronal injury in RIBI. It also provides a therapeutic strategy by targeting HMGB1-TLR2/TLR4/RAGE signaling pathway in the microglia for the treatment of RIBI.
What problem does this paper attempt to address?